Siemens Healthineers Stock: Market Unmoved by Key FDA Clearance

Siemens Healthineers stock hits 52-week low despite FDA expanding Varian radiation therapy to treat osteoarthritis, a move aimed at boosting equipment use in a vast patient market.

Siemens Healthineers shares have continued their downward trajectory, hitting a fresh 52-week low last Friday. This decline occurred despite the company achieving a significant regulatory milestone in the United States that substantially broadens the commercial potential for its radiation therapy technology.

FDA Greenlights New Use for Varian Systems

The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for a novel application of Varian linear accelerator platforms, including TrueBeam, VitalBeam, and Edge. Previously approved primarily for precise cancer treatment, these high-end systems can now be used in the U.S. to treat adults with severe osteoarthritis who have found no relief from standard therapies.

This approval opens the door for a low-dose radiation therapy aimed at modulating inflammatory processes and alleviating pain. It is positioned as a non-invasive, outpatient alternative to existing interventions for chronic joint degeneration.

Tapping into a Vast Patient Population

The economic implications for hospitals and specialized treatment centers are considerable. They can now utilize their existing Varian hardware for a much wider patient base, significantly optimizing the utilization rates of this costly equipment. The potential market is substantial, with over 33 million adults in the United States alone affected by osteoarthritis.

Persistent Investor Skepticism Overshadows News

The strategic expansion into this new therapeutic mass market has, however, failed to impress investors. On Friday, Siemens Healthineers stock slid a further 2.28 percent to close at €36.37, precisely marking its lowest point in a year. Since the start of the year, the share price has now fallen by more than 18 percent, highlighting sustained market skepticism.

The company is advancing other areas alongside radiation therapy, including imaging with new AI-powered planning software for liver cancer and cost-effective upgrades for angiography systems. To reverse the persistent negative trend, management must now demonstrate that U.S. clinics will rapidly adopt this new approach for joint diseases.

The key to a fundamental re-rating of the stock lies in translating the expanded FDA clearance into tangible business results. Once the approval leads to higher equipment utilization rates and concrete new orders for the Varian division, the company will have solid arguments for a renewed investor assessment.